Evaluates nephroprotective activity of indolizidine alkaloids in kidney cells, suggesting potential for chemotherapy patients.
Three new indolizidine alkaloids, bohemindolizidines C–E (1–3), together with two known analogues bohemindolizidines A and B (4 and 5) were isolated from marine-derived Streptomyces sp. KIB629. Their structures were established by a comprehensive analysis of NMR, HRESIMS, ECD and X-ray crystallography. All isolates were evaluated for nephroprotective activity against cisplatin-induced cytotoxicity in human embryonic kidney 293 (HEK293) cells. Compounds 1 and 4 exhibited significant protective effects with EC50 values of 10.00 μM and 4.28 μM, respectively. These results indicate that bohemindolizidines are promising candidates as nephroprotective agents for patients undergoing cisplatin chemotherapy.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: